Search
Advertisement
neetu chandra sharma
Neetu Chandra Sharma

Neetu Chandra Sharma

tvtn

neetu.chandra@aajtak.com

Neetu Chandra Sharma is a Senior Editor at Business Today, where she leads the magazine’s coverage of healthcare and pharmaceuticals. With over two decades of experience in top Indian newsrooms—including Mint, Hindustan Times, the India Today Group, and Zee Media—she has consistently reported on the intersection of public health policy, corporate healthcare, and the pharmaceutical industry. Her journalism spans policy deep dives, industry trends, regulatory shifts, and corporate strategy across India’s thriving hea...

SHOW MORE...

For Zydus, the transaction also adds a direct commercial interface with oncologists and specialty-care providers in the US, where it has been expanding its complex generics and specialty portfolio.

Zydus buys assertio for $166 million to deepen US specialty and oncology presence

by Neetu Chandra Sharma |May 13, 2026

Acquisition gives the company access to an oncology supportive-care product, front-end commercial operations and a specialty portfolio in the US.

Executives in the diagnostics industry say organised chains are gaining market share as consumers increasingly prioritise quality, accuracy and advanced testing.

Metropolis sees growth from preventive and specialised diagnostics

by Neetu Chandra Sharma |May 13, 2026

Diagnostics chain expands beyond 5,000 centres as preventive healthcare, specialised testing and hospital partnerships support growth.

Aiming for the Sun: How the $11.75 billion Organon buy is cementing Dilip Shanghvi’s legacy

Aiming for the Sun: How the $11.75 billion Organon buy is cementing Dilip Shanghvi’s legacy

by Neetu Chandra Sharma |May 13, 2026

Sun Pharmaceutical Industries has struck its largest global deal to acquire US-based Organon for $11.75 billion. This deal expands Sun Pharma's footprint to 150 markets. Will it pay off?

Cipla reported revenue of ₹28,163 crore in FY26, while net profit stood at ₹3,879 crore.

Cipla focuses on respiratory therapies, specialty drugs and complex generics

by Neetu Chandra Sharma |May 13, 2026

India business crosses ₹12,680 crore in FY26 as Cipla expands specialty pipeline, respiratory portfolio and regulated market presence

The launch comes at a time when India is witnessing a rapid rise in dementia cases driven by an ageing population, low awareness and delayed diagnosis.

Lilly launches Alzheimer’s therapy Lormalzi in India as dementia burden rises

by Neetu Chandra Sharma |May 13, 2026

Once-monthly drug aims to slow cognitive decline in patients with early-stage Alzheimer’s disease

For the year ended March 31, 2026, GSK India reported revenue of ₹3,790 crore, up 2%, while profit after tax rose 10% to ₹1,012 crore.

GSK India’s growth shifts to cancer therapies and adult vaccines

by Neetu Chandra Sharma |May 13, 2026

New oncology approvals and specialty medicines begin contributing more as traditional portfolios face slower growth

Dr Reddy’s Turns To Obesity Drugs, Biosimilars And Consumer Health For Next Phase Of Growth

Dr Reddy’s Turns To Obesity Drugs, Biosimilars And Consumer Health For Next Phase Of Growth

by Neetu Chandra Sharma |May 13, 2026

Dr. Reddy's Laboratories is increasing focus on obesity therapies, biosimilars, peptides and consumer healthcare as lower sales from its cancer drug business in the US market weigh on growth. The comp...

Dr Reddy’s revenues from India rose 20% year-on-year in the March quarter and 16% for the full year, supported by new launches, price increases, higher volumes and acquired portfolios.

After Lenalidomide, Dr Reddy’s turns to obesity drugs, biosimilars and consumer health

by Neetu Chandra Sharma |May 12, 2026

Hyderabad-based drugmaker enters a new growth phase as pressure rises on its US generics business

Kiran Mazumdar-Shaw On Claire Mazumdar & Biocon’s Future

Kiran Mazumdar-Shaw On Claire Mazumdar & Biocon’s Future

by Neetu Chandra Sharma |May 11, 2026

Biocon Founder Kiran Mazumdar-Shaw joins Business Today TV for an exclusive conversation on Biocon’s next phase of growth, leadership transition and the global biosimilars opportunity. As Claire Mazum...

Kiran Mazumdar-Shaw Reveals Biocon Succession Plan In First Interview After Announcement

Kiran Mazumdar-Shaw Reveals Biocon Succession Plan In First Interview After Announcement

by Neetu Chandra Sharma |May 11, 2026

Biocon Executive Chairperson Kiran Mazumdar-Shaw speaks exclusively to Business Today TV in her first interview after announcing Claire Mazumdar as her successor. In this special conversation, Kiran S...